본문으로 건너뛰기
← 뒤로

Evolving Neoadjuvant, Adjuvant, and Concurrent Systemic Therapy Strategies in Head and Neck Squamous Carcinoma.

1/5 보강
Otolaryngologic clinics of North America 📖 저널 OA 2.3% 2021: 0/3 OA 2022: 0/6 OA 2023: 1/13 OA 2024: 0/4 OA 2025: 2/17 OA 2026: 0/20 OA 2021~2026 2026 Vol.59(1) p. 127-146
Retraction 확인
출처

Menon N

📝 환자 설명용 한 줄

The role of cytotoxic chemotherapy in the neoadjuvant setting has not been well established by older studies, except in the case of larynx preservation.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Menon N (2026). Evolving Neoadjuvant, Adjuvant, and Concurrent Systemic Therapy Strategies in Head and Neck Squamous Carcinoma.. Otolaryngologic clinics of North America, 59(1), 127-146. https://doi.org/10.1016/j.otc.2025.08.022
MLA Menon N. "Evolving Neoadjuvant, Adjuvant, and Concurrent Systemic Therapy Strategies in Head and Neck Squamous Carcinoma.." Otolaryngologic clinics of North America, vol. 59, no. 1, 2026, pp. 127-146.
PMID 41152067 ↗

Abstract

The role of cytotoxic chemotherapy in the neoadjuvant setting has not been well established by older studies, except in the case of larynx preservation. Novel neoadjuvant strategies are being explored, such as the incorporation of immune checkpoint inhibitors into the neoadjuvant/peri-operative setting, novel combinations of chemotherapy with ICI and/or metronomic therapy, and the use of neoadjuvant chemo-immunotherapy for response-adapted de-escalation of radiotherapy. IAP (inhibitor of apoptosis protein) antagonists are novel agents being investigated in HNSCC, but have not shown benefit in the phase III setting.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반